BIO-RAD LABORATORIES, INC. Equity Securities, FV-NI, Unrealized Loss
BIO-RAD LABORATORIES, INC. (BIO) reported Equity Securities, FV-NI, Unrealized Loss of $505.10 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2025-10-29
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2025-09-30 was $505.10M.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2024-12-31 was $970.60M.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2024-09-30 was -$761.10M.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2024-06-30 was $2.87B.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for fiscal 2024 was $2.68B, a 112.93% increase from fiscal 2023.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for fiscal 2023 was $1.26B, a 75.16% decline from fiscal 2022.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized loss for fiscal 2022 was $5.07B.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2025-09-30 | $505.10M 10-Q · filed 2025-10-29 | $149.50M 10-Q · filed 2025-10-29 | ||
| 2024-12-31 | $970.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $209.50M derived: sum of 2 quarters · filed 2025-02-14 | $3.08B derived: sum of 3 quarters · filed 2025-02-14 | $2.68B 10-K · filed 2025-02-14 |
| 2024-09-30 | -$761.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.11B derived: sum of 2 quarters · filed 2024-10-31 | $1.71B 10-Q · filed 2024-10-31 | $1.41B derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-06-30 | $2.87B 10-Q · filed 2024-08-02 | $2.47B 10-Q · filed 2024-08-02 | $2.18B derived: sum of 3 quarters · filed 2025-02-14 | |
| 2024-03-31 | -$402.30M derived: 10-K 12 month − 3 quarters · filed 2025-02-14 | -$699.00M derived: sum of 2 quarters · filed 2025-02-14 | ||
| 2023-12-31 | -$296.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $1.26B 10-K · filed 2024-02-16 | ||
| 2023-09-30 | $1.56B 10-Q · filed 2023-10-27 | |||
| 2023-03-31 | $20.10M 10-Q · filed 2023-05-05 | -$909.90M derived: sum of 2 quarters · filed 2023-05-05 | -$639.90M derived: sum of 3 quarters · filed 2023-05-05 | |
| 2022-12-31 | -$930.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$660.00M derived: sum of 2 quarters · filed 2023-02-17 | $5.07B 10-K · filed 2023-02-17 | |
| 2022-09-30 | $270.00M 10-Q · filed 2022-10-28 | $6.00B 10-Q · filed 2022-10-28 |